Druggability of CRMP2 for Neurodegenerative Diseases.
Saved in:
| Title: | Druggability of CRMP2 for Neurodegenerative Diseases. |
|---|---|
| Authors: | Khanna R; Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States.; Graduate Interdisciplinary Program in Neuroscience, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States.; The Center for Innovation in Brain Sciences, The University of Arizona Health Sciences, Tucson, Arizona 85724, United States.; Regulonix LLC, Tucson, Arizona 85718, United States., Moutal A; Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States., Perez-Miller S; Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States., Chefdeville A; Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States., Boinon L; Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States., Patek M; BrightRock Path, LLC, Tucson, Arizona 85704, United States. |
| Source: | ACS chemical neuroscience [ACS Chem Neurosci] 2020 Sep 02; Vol. 11 (17), pp. 2492-2505. Date of Electronic Publication: 2020 Aug 04. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Review |
| Journal Info: | Publisher: American Chemical Society Country of Publication: United States NLM ID: 101525337 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1948-7193 (Electronic) Linking ISSN: 19487193 NLM ISO Abbreviation: ACS Chem Neurosci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
